Lv1
82 积分 2024-09-11 加入
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
11小时前
已完结
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
11小时前
已完结
Association of resting heart rate with cognitive decline and dementia in older adults: A population‐based cohort study
5天前
已完结
Heart rate as a predictor of cardiovascular risk
5天前
已完结
CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects
6天前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
6天前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
6天前
已完结
Bi 456906, structural properties and pharmacology of the novel glucagon and glucagon - like peptide - 1 receptor (GCGR/GLP - 1R) dual agonist
6天前
已完结
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
6天前
已完结
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
6天前
已完结
皖公网安备34019202002308
